D0011 | Atenolol

Molecular Formula C14H22N2O3
Molecular Weight 266.34
State solid
Clearance Total clearance is estimated at 97.3-176.3 mL/min with a renal clearance of 95-168 mL/min.[A178180]
Volume of distribution Total Vd of 63.8-112.5 L. Atenolol distributes into a central volume of 12.8-17.5 L along with two peripheral compartments with a combined volume of 51-95 L.[A178180] Distribution takes about 3 hrs for the central compartment, 4 hrs for the shallower peripheral compartment, and 5-6 hrs for the deeper peripheral compartment.
Route of elimination 85% is eliminated by the kidneys following IV administration with 10% appearing in the feces.[label,A178180]
Protein binding 6-16% bound in plasma.[label] Atenolol binds to two sites on human serum albumin.[A178210]
Half life 6-7 hrs.[label]
Absorption Approximately 50% of an oral dose is absorbed from the gastrointestinal tract, with the remainder being excreted unchanged in the feces.[label] Administering atenolol with food can decrease the AUC by about 20%.[A178180] While atenolol can cross the blood-brain barrier, it does so slowly and to a small extent.
Description cardioselective beta-blocker


C07FB03 Atenolol and nifedipine

[C07FB] Beta blocking agents and calcium channel blockers



[C] Cardiovascular system

C07DB01 Atenolol, thiazides and other diuretics

[C07DB] Beta blocking agents, selective, thiazides and other diuretics



[C] Cardiovascular system

C07CB53 Atenolol and other diuretics, combinations

[C07CB] Beta blocking agents, selective, and other diuretics



[C] Cardiovascular system

C07CB03 Atenolol and other diuretics

[C07CB] Beta blocking agents, selective, and other diuretics



[C] Cardiovascular system

C07BB03 Atenolol and thiazides

[C07BB] Beta blocking agents, selective, and thiazides



[C] Cardiovascular system

C07AB03 Atenolol

[C07AB] Beta blocking agents, selective



[C] Cardiovascular system

Toxicity Dose Time Species Model Method Action Positive criterion Reference
GLUCOSE GALACTOSE IC50 RATIO 300.0 ± 0, 300.0 ± 0, 1, 300.0 ± 0, 300.0 ± 0, 1 4hr H9c2 cells high-glucose–galactose cell viability assay with mitochondrial membrane potential (JC-1) and ATP-depletion assays (CellTiter-Glo reagent ). Negative glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla )(μM) 50

Pictogram Signal Statements Precautionary Statement Codes

Aggregated GHS information provided by 87 companies from 22 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Reported as not meeting GHS hazard criteria by 3 of 87 companies. For more detailed information, please visit ECHA C&L website

Of the 20 notification(s) provided by 84 of 87 companies with hazard statement code(s):

H302 (82.14%): Harmful if swallowed [Warning Acute toxicity, oral]

H319 (69.05%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

H351 (67.86%): Suspected of causing cancer [Warning Carcinogenicity]

H362 (77.38%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]

Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.

P201, P202, P260, P263, P264, P270, P280, P281, P301+P312, P305+P351+P338, P308+P313, P330, P337+P313, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
mouse LD50 subcutaneous > 400mg/kg (400mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 8, Pg. 4579, 1980.
women TDLo oral 16mg/kg (16mg/kg) lungs, thorax, or respiration: respiratory obstruction Annals of Emergency Medicine. Vol. 14, Pg. 161, 1985.
mouse LD50 intraperitoneal 134mg/kg (134mg/kg) Toksikologicheskii Vestnik. Vol. (4), Pg. 33, 1995.
rat LD50 intravenous 84mg/kg (84mg/kg) PCT Vol. #91-10428,
women TDLo oral 1080mg/kg/78W (1080mg/kg) Journal of Rheumatology. Vol. 13, Pg. 446, 1986.
rat LD50 intravenous 77mg/kg (77mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 8, Pg. 4579, 1980.
rat LD50 oral > 2gm/kg (2000mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 8, Pg. 4579, 1980.
mouse LD50 oral 2gm/kg (2000mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 8, Pg. 4579, 1980.
man TDLo oral 10204ug/kg (10.204mg/kg) Anesthesiology. Vol. 83, Pg. 204, 1995.
rat LD50 subcutaneous > 600mg/kg (600mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 8, Pg. 4579, 1980.
women TDLo oral 42mg/kg/3W-I (42mg/kg) British Medical Journal. Vol. 294, Pg. 1324, 1987.
mouse LD50 intravenous 57mg/kg (57mg/kg) peripheral nerve and sensation: flaccid paralysis without anesthesia (usually neuromuscular blockage) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 8, Pg. 4579, 1980.
rabbit LD50 intravenous 50mg/kg (50mg/kg) Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. Vol. 17, Pg. 425, 1979.
rat LD50 intravenous 97mg/kg (97mg/kg) PCT Vol. #91-10428,
man TDLo oral 129mg/kg/26W- (129mg/kg) Annales de Medecine Interne. Vol. 148, Pg. 505, 1997.
man TDLo oral 86mg/kg/60D-I (86mg/kg) blood: "changes in serum composition (e.g., tp, bilirubin, cholesterol)" American Journal of Medicine. Vol. 85, Pg. 586, 1988.
man TDLo oral 49mg/kg/30D-I (49mg/kg) behavioral: excitement Journal of Clinical Pyschopharmacology. Vol. 6, Pg. 390, 1986.

  • Acute coronary syndrome

  • Acute myocardial infarction

  • Angina pectoris

  • Arrhythmia

  • Arteriosclerosis coronary artery

  • Asthma

  • Bradycardia

  • Cardiac failure

  • Chest pain

  • Diabetes mellitus

  • Diabetic nephropathy

  • Foetor hepaticus

  • Hepatocellular injury

  • Hyperlipidaemia

  • Hypotension

  • Liver disorder

  • Myocardial infarction

  • Myocardial ischaemia

  • Renal failure

  • Renal impairment

  • Systolic hypertension

  • Tachycardia

  • Ventricular arrhythmia

  • Arrhythmia

  • Asthenia

  • Atrial fibrillation

  • Atrial flutter

  • Atrioventricular block

  • Bradycardia

  • Bronchospasm

  • Cardiac arrest

  • Cardiac failure

  • Cardiac septal defect

  • Cardiogenic shock

  • Depression

  • Diarrhoea

  • Dizziness

  • Dyspnoea

  • Fatigue

  • Hypotension

  • Lethargy

  • Mitral valve incompetence

  • Myocardial infarction

  • Nausea

  • Orthostatic hypotension

  • Pain in extremity

  • Peripheral coldness

  • Regurgitation

  • Renal failure

  • Somnolence

  • Supraventricular tachycardia

  • Ventricular septal defect

  • Ventricular tachycardia

  • Vertigo

  • ( inverted question mark)-Atenolol (+)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide (+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide
    (+-)-Atenolol (+/-)-4-(2-Hydroxy-3-[(1-methylethyl)amino]propoxy)benzeneacetamide (+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide
    (+/-)-Atenolol (1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide (?)-Atenolol
    (A+/-)-Atenolol (RS)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide (RS)-Atenolol
    (r,s)-atenolol (y)-Atenolol 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol
    122A687 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid 2-(4-(2-hydroxy-3-(isopropylamino)propoxy)
    2-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide 2-(4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl)acetamide 2-(4-{2-hydroxy-3-[(methylethyl)amino]propoxy}phenyl)acetamide
    2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide 2-(4-{[(2S)-2-hydroxy-3-(propan-2-ylamino)propyl]oxy}phenyl)acetamide 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide
    2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide 2-[4-({(2R)-2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide
    2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide 2-{4-[2-Hydroxy-3-(isopropylamino)propoxy]-phenyl}acetamide 2-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide
    2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide 29122-68-7 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide
    4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide 60966-51-0 A 7655
    AB00052208-13 AB00052208-15 AB00052208_16
    AB0011597 AC-8245 AKOS005111050
    ANW-45215 API0001553 ARONIS23884
    AX8005715 Acetamide, 2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)- Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)
    Aircrit Alinor Altol
    Anselol Antipressan Apo-Atenolol
    Artrenolol Atcard Atcardil
    Atecard Atehexal Atenblock
    Atendol Atenet Ateni
    Atenil Atenol Atenol 1A pharma
    Atenol AL Atenol Atid Atenol Cophar
    Atenol Fecofar Atenol GNR Atenol Gador
    Atenol Genericon Atenol Heumann Atenol MSD
    Atenol NM Pharma Atenol Nordic Atenol PB
    Atenol Quesada Atenol Stada Atenol Tika
    Atenol Trom Atenol acis Atenol ct
    Atenol von ct Atenol-Mepha Atenol-Wolff
    Atenol-ratiopharm Atenolin Atenolol (JAN/USP)
    Atenolol (JP17/USP/INN) Atenolol 1.0 mg/ml in Acetonitrile Atenolol 100 microg/mL in Methanol
    Atenolol Bp Atenolol [USAN:BAN:INN:JAN] Atenolol [USAN:INN:BAN:JAN]
    Atenolol [USAN:USP:INN:BAN:JAN] Atenolol solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material Atenolol, 98%
    Atenolol, >=98% (TLC), powder Atenolol, European Pharmacopoeia (EP) Reference Standard Atenolol, Pharmaceutical Secondary Standard
    Atenolol, United States Pharmacopeia (USP) Reference Standard Atenolol, analytical reference material Atenolol,(S)
    Atenololum Atenololum [INN-Latin] Atenomel
    Atereal Aterol BBC/163
    BBL009276 BB_SC-01519 BCP12899
    BIM-0050109.0001 BRD-A20239487-001-02-5 BRD-A20239487-001-15-7
    BRN 2739235 BSPBio_002915 Benzeneacetamide, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-
    Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- Betablok Betacard
    Betasyn Betatop Ge Blocotenol
    Blokium CA0145 CAS-29122-68-7
    CCG-39010 CCRIS 4196 CHEBI:2904
    CHEMBL24 CPD000036768 CS-2927
    CTK3J2163 Cardaxen Cardiopress
    Certified Reference Material Corotenol Cuxanorm
    D00235 DB-072177 DB-079552
    DB00335 DSSTox_CID_2628 DSSTox_GSID_22628
    DSSTox_RID_76663 DTXSID2022628 DivK1c_000057
    Duraatenolol EINECS 249-451-7 EINECS 262-544-7
    EN300-119532 EU-0100121 Evitocor
    FT-0622499 FT-0693045 Farnormin
    Felo-Bits GEO-03413 GTPL548
    HMS1569L13 HMS1921H09 HMS2090I19
    HMS2092D19 HMS2233E06 HMS3259K08
    HMS3260I04 HMS3266K13 HMS3369B14
    HMS3369D20 HMS3369P20 HMS3411G21
    HMS3675G21 HMS500C19 HSDB 6526
    HY-17498 Hipres Hypoten
    ICI 66,082 ICI 66082 ICI-66082
    IDI1_000057 Ibinolo InChI=1/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
    Internolol J10009 Jenatenol
    Juvental KBio1_000057 KBio2_001844
    KBio2_004412 KBio2_006980 KBio3_002415
    KBioGR_000790 KBioSS_001844 KS-00000XIG
    KS-000046IQ KS-5341 KSC492C6H
    L000116 LP00121 LS-28557
    LS-9707 Lo-ten Lopac0_000121
    Loten Lotenal MCULE-9148694071
    MLS000069622 MLS001066372 MLS001074163
    MLS001304038 MRF-0000571 Myocord
    NC00548 NCGC00015007-06 NCGC00015007-07
    NCGC00015007-08 NCGC00015007-09 NCGC00015007-10
    NCGC00015007-11 NCGC00015007-13 NCGC00024566-03
    NCGC00024566-04 NCGC00024566-05 NCGC00024566-06
    NCGC00024566-07 NCGC00255122-01 NCGC00260806-01
    NINDS_000057 NSC-757832 NSC757832
    Neatenol Normalol Normiten
    Noten Opera_ID_1283 Oprea1_448775
    Oraday Ormidol Panapres
    Pharmakon1600-01501127 Plenacor Premorine
    Prenolol Prenormine Prinorm
    Q-200656 Q411325 RTR-012731
    SAM002564193 SBB056998 SBI-0050109.P003
    SC-19545 SCHEMBL4362 SMR000036768
    SPBio_001482 SPECTRUM1501127 SR-01000000159
    SR-01000000159-2 SR-01000000159-4 SR-01000000159-5
    SR-01000000159-8 ST024754 ST2403914
    STK528649 Scheinpharm Atenol Seles beta
    Selobloc Serten Servitenol
    Spectrum2_001411 Spectrum3_001448 Spectrum4_000435
    Spectrum5_001509 Spectrum_001364 Stermin
    TR-012731 Tenidon Teno-basan
    Tenobloc Tenoblock Tenolol
    Tenoprin Tenoretic (Salt/Mix) Tenormin
    Tenormin (TN) Tenormine Tenormine [French]
    Tensimin Tensotin Tox21_302426
    Tox21_500121 Tredol Unibloc
    Uniloc Vascoten Vericordin
    Wesipin Xaten Z-0828
    Z1541638518 ZX-AS004380 atenolol
    benzeneacetamide, 4-[2'-hydroxy-3;-[(1-methylethyl)amino]propoxy]- dl-Atenolol duratenol

    DrugBank Name Atenolol
    DrugBank DB00335
    CAS Number 106020-65-9, 1309283-20-2, 29122-68-7, 56715-13-0, 60966-51-0, 93379-54-5
    PubChem Compound 2249
    KEGG Drug D00235
    PubChem.Substance 46506915
    ChEBI 2904
    PharmGKB PA448499
    ChemSpider 2162
    BindingDB 25753.0
    TTD DAP000482
    Wikipedia Atenolol
    DPD 2041

    1. Dykens et al. (2007)